Claim 70% Off TipRanks This Holiday Season
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
An update from Tiziana Life Sciences ( (TLSA) ) is now available.
On December 19, 2025, Tiziana Life Sciences announced that Panetta Partners Limited, an entity in which Executive Chairman Gabriele Cerrone has a beneficial interest, purchased 97,687 additional common shares, increasing Cerrone’s total holding to 43,374,830 shares, or 36.08% of the company’s issued share capital. The move further concentrates ownership in the hands of Tiziana’s top leadership, underscoring insider confidence in the company’s intranasal foralumab program and broader immunomodulation platform at a pivotal clinical stage for its multiple sclerosis and neuroinflammatory disease pipeline.
The most recent analyst rating on (TLSA) stock is a Buy with a $8.00 price target. To see the full list of analyst forecasts on Tiziana Life Sciences stock, see the TLSA Stock Forecast page.
More about Tiziana Life Sciences
Tiziana Life Sciences Ltd is a clinical-stage biopharmaceutical company focused on developing breakthrough immunomodulation therapies using alternative drug delivery technologies, particularly intranasal administration, to improve the efficacy, safety and tolerability of immunotherapy. Its lead product candidate is intranasal foralumab, the only fully human anti-CD3 monoclonal antibody currently in clinical development, being tested for neuroinflammatory and neurodegenerative diseases such as non-active secondary progressive multiple sclerosis, where early expanded access use has shown either disease improvement or stability in all 14 patients treated within six months.
Average Trading Volume: 350,002
Technical Sentiment Signal: Hold
Current Market Cap: $173.5M
Find detailed analytics on TLSA stock on TipRanks’ Stock Analysis page.